iShares Biotechnology ETF
845 hedge funds and large institutions have $7.67B invested in iShares Biotechnology ETF in 2021 Q1 according to their latest regulatory filings, with 82 funds opening new positions, 293 increasing their positions, 270 reducing their positions, and 80 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 293 | Existing positions reduced: 270
3% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 80
1% less funds holding
Funds holding: 856 → 845 (-11)
8.67% less ownership
Funds ownership: 85.34% → 76.67% (-8.7%)
14% less capital invested
Capital invested by funds: $8.9B → $7.67B (-$1.23B)
47% less funds holding in top 10
Funds holding in top 10: 15 → 8 (-7)
60% less call options, than puts
Call options by funds: $329M | Put options by funds: $825M
Top Buyers
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$242M |
| 2 |
JP Morgan Chase
New York
|
+$234M |
| 3 |
Citigroup
New York
|
+$66.8M |
| 4 |
CI Investments Inc
Toronto,
Ontario, Canada
|
+$61.6M |
| 5 |
Millennium Management
New York
|
+$35.8M |
Top Sellers
IBB Hedge Fund Activity: Q1 2021 in Review
845 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2021, worth a combined $7.67B — down 14% from $8.9B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new IBB positions and 80 closed out — a net gain of 2 holders — while 293 added to existing stakes and 270 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $242M. The largest seller was Goldman Sachs, cutting an estimated $463M.
- 845 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2021, down from 856 in Q4 2020.
- Funds reported $7.67B of iShares Biotechnology ETF stock for Q1 2021, down 14% quarter-over-quarter.
- 82 funds opened new iShares Biotechnology ETF positions in Q1 2021 and 80 closed out, a net change of +2 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2021 was BNP Paribas Financial Markets, an estimated $242M added.
- The largest iShares Biotechnology ETF seller in Q1 2021 was Goldman Sachs, an estimated $463M sold.
Based on aggregated 13F filings for Q1 2021.